Revolution Medicines, Inc. reiterated full year 2022 GAAP net loss to be between $260 million and $290 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.21 USD | +1.78% |
|
-1.06% | +33.23% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.23% | 6.3B | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2022